InferVision expands FDA change-control scope for surgical-planning AI
Source publication date
Site published
The principal change from K250237 is an expanded PCCP, permitting validated future MR support for existing CT organs and additional organ segmentation.
Summary
FDA cleared InferOperate Suite under K260973 on July 7.
Editorial view
Editorial view: controlled post-launch updates are part of medical-AI product strategy.
Evidence and limitations
Planned changes are not proof of released functionality. Clinicians retain final decisions; ML use covers chest, abdominal and pelvic CT in patients 21+. This record does not establish hospital adoption or outcome improvement.